PDCD1 and non-small cell lung carcinoma: ICIs, including anti‐PD‐1, anti‐PD‐L1, and anti‐CTLA‐4 antibodies, have shown great promising benefit in clinical trials and have been rapidly incorporated into the standard management of advanced stage NSCLC.